SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Mumtaz Mahal

PatientMumtaz Mahal
Date of birth1988-04-27
IdentifiersMRN HR-RE006-SYN; SSN (made up) 000-06-7184
Document date2026-06-02
AuthorFarzana Qureshi-Lindholm, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Prenatal visit at 34 weeks after six weeks of travel; growth scan and birth planning. [S]

History of Present Illness

Mumtaz Mahal returns at 34 weeks 2 days, three days after coming back from six weeks of travel with her family. The visits planned at 30 and 32 weeks did not take place: the family moved several times and no clinic was arranged, and no blood pressure was checked while she was away. She has felt well. She has had no headache, visual change, upper abdominal pain, swelling of the face or hands, breathlessness, bleeding, leaking fluid, or regular contractions; she has occasional painless tightenings, and the baby moves often. She took aspirin and folic acid throughout. The test-of-cure urine culture sent before she left grew nothing. She is staying in the city until the birth. She had the growth scan this morning. She has thought about the future and says she wants her body to rest after this baby. [S]

ElementDetail
TravelSix weeks away; the 30- and 32-week visits were missed
SymptomsNone of preeclampsia; occasional painless tightenings
Fetal movementFrequent
UrineTest-of-cure culture: no growth
PlansStaying near the hospital until the birth

Review of Systems

SystemResultFinding
ConstitutionalNegativeWell; no fever
CardiovascularNegativeNo breathlessness or palpitations
NeurologicalNegativeNo headache or visual change
GastrointestinalNegativeNo upper abdominal pain or vomiting
GenitourinaryNegativeNo bleeding, leaking fluid, or urinary symptoms
PsychiatricNegativeCalm and hopeful; EPDS 5

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-06activeS
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other dayOne tablet every other morning with water or orange juice, apart from tea and calciumOral route2026-01-06 to 2026-02-03completedS
Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtime until deliveryOral route2026-01-06activeS
Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily for 5 daysOne capsule twice daily with food for 5 daysOral route2026-03-24 to 2026-03-29completedS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses)Single infusion; two doses in total, four weeks apartIntravenous route2026-02-03 to 2026-02-03completedS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses)Single infusion; two doses in total, four weeks apartIntravenous route2026-03-03 to 2026-03-03completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-02Body height157cmS
2026-06-02Body weight68kgS
2026-06-02Body mass index (BMI) [Ratio]27.6kg/m2S
2026-06-02Systolic blood pressure112mm[Hg]S
2026-06-02Diastolic blood pressure70mm[Hg]S
2026-06-02Heart rate88/minS
2026-06-02Respiratory rate16/minS
2026-06-02Body temperature36.8CelS
2026-06-02Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-02Hemoglobin [Mass/volume] in Blood11.8g/dL11-15 g/dLNormalS
2026-06-02Platelets [#/volume] in Blood by Automated count22810*3/uL150-400 10*3/uLNormalS
2026-06-02Total score [EPDS]5{score}S
2026-06-02Fetal Body weight estimated by US2380gAbout the 45th centile for 34 weeksNormalS

Physical Exam

Vital signs recorded on 2026-06-02; see the Vital Signs section. [S]

SystemFinding
GeneralWell
AbdomenFundal height 34 cm; cephalic by palpation; non-tender
FetalScan: cephalic, estimated weight 2380 g (about the 45th centile), normal amniotic fluid; fetal heart 140 per minute
ExtremitiesTrace ankle edema; no calf tenderness
Urine dipstickProtein negative

Problems

ProblemClinical statusVerificationCodeProvenance
Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12activeconfirmed O09.529S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic.
Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living childrenactiveconfirmed O09.40S — Synthetic modern problem anchored to her documented thirteen earlier births.
Short interpregnancy interval: conception about five and a half months after her last birthactiveconfirmed O09.899S — Synthetic modern problem anchored to the documented fourteen months between her last two births.
Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mLactiveconfirmed O99.019S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis.
Acute cystitis in pregnancy at 24 weeks: dysuria and frequency, no fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; treated and resolvedresolvedconfirmed O23.12S — Synthetic intercurrent infection at an unscheduled visit; common in pregnancy and in multiparous women. It echoes no documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure and urine proteinEvery prenatal visitCompleted today112/70 mmHg; urine protein negative
ExaminationBlood pressure and fetal checks at 30 and 32 weeksEvery two weeks from 28 to 36 weeksDeferredMissed: the 30- and 32-week visits did not take place during six weeks of family travel, and no blood pressure was recorded. No harm found today: blood pressure 112/70 mmHg, no proteinuria, no symptoms, and normal growth on the scan. Corrective action: weekly visits until the birth, a home blood pressure cuff with readings to call in, and she will stay near the hospital
ExaminationFetal heart and fundal heightEvery prenatal visitCompleted todayFetal heart 140 per minute; fundal height 34 cm; cephalic
ExaminationWeight gainEvery prenatal visitCompleted today68.0 kg, up 9.4 kg since intake
LaboratoryHemoglobin and ferritinAt intake, four weeks after starting treatment, at 24 to 28 weeks, and before deliveryCompleted todayHemoglobin 11.8 g/dL: anemia corrected before delivery; platelets 228
ImagingThird-trimester growth scanAt about 32 to 34 weeksCompleted todayEstimated weight 2380 g, about the 45th centile; cephalic; normal fluid
LaboratoryUrine culture test of cureOne to two weeks after treatmentCompleted todayNo growth (sent at the 27-week visit)
LaboratoryGroup B streptococcus cultureAt 36 0/7 to 37 6/7 weeksDueAt the 36-week visit
SurveyPerinatal mood screen (EPDS)Each trimesterCompleted today5; item 10 scored 0
Medication safetyLow-dose aspirinDaily from 12 to 16 weeks until delivery; review at every visitCompleted todayTaken nightly; continue until delivery
Self-managementPostpartum hemorrhage risk assessment and birth planAt intake, in the third trimester, and on admission for birthCompleted todayMedium risk from grand multiparity; written plan agreed: hospital birth, oxytocin, quantitative blood loss, tranexamic acid within 3 hours if hemorrhage occurs
ReferralAnesthesia consultationIn the third trimester for a patient at increased risk of hemorrhageDueBooked for 36 weeks
Self-managementPostpartum contraception and interpregnancy intervalBefore deliveryCompleted todayEtonogestrel implant before discharge; at least 18 to 24 months before any future pregnancy

Goal progress:

Guideline basis: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Practice Bulletin No. 183: Postpartum Hemorrhage (2017); WHO recommendations for the prevention and treatment of postpartum haemorrhage (2012); WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017); Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial (2017); Obstetric Care Consensus No. 8: Interpregnancy Care (2019); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024)

Follow-up: Weekly prenatal visits from next week until the birth; induction at 39 weeks at the hospital. [S]